Literature DB >> 10525120

Contribution of apolipoprotein(a) size, pentanucleotide TTTTA repeat and C/T(+93) polymorphisms of the apo(a) gene to regulation of lipoprotein(a) plasma levels in a population of young European Caucasians.

K Valenti1, E Aveynier, S Leauté, F Laporte, A J Hadjian.   

Abstract

Several studies indicate that the inter-individual variation in plasma concentrations of lipoprotein(a) (Lp(a)) is mainly under genetic control. To define the effect of three DNA polymorphisms on apolipoprotein(a) (apo(a)) expression, we have determined plasma Lp(a) concentrations, apo(a) isoform size, KpnI allele size, the TTTTA pentanucleotide repeat number in the 5' control region of the apo(a) gene and the +93 C/T polymorphism in a European Caucasian population. The simultaneous determination of the kringle 4 (K4) number by genotyping and by phenotyping revealed that the size distribution of non-expressed apo(a) alleles was markedly skewed towards alleles with greater than 25 K4 repeats. This is consistent with the inverse relationship frequently described between the kringle 4 number and the plasma Lp(a) level. Apportioning the Lp(a) concentration from the surface of the peaks on apo(a) phenotyping blots, we have observed that the Lp(a) plasma concentration associated with alleles having more than 25 K4 units does not exceed 400 mg/l, whereas the range of Lp(a) concentrations associated with smaller alleles was broad, from 0 to more than 1000 mg/l. It can thus be concluded that the number of K4 repeats is the main determinant of Lp(a) concentration when this number is more than 25, whereas other polymorphisms may be involved in the alleles with fewer than 26 K4. Analyses of the TTTTA repeat number and of the +93 C/T polymorphism were performed in subjects with KpnI alleles of the same length: low Lp(a) concentrations were shown to be preferentially associated with the presence of apo(a) alleles with more than eight pentanucleotide repeats while no association was revealed between Lp(a) plasma levels and the C/T polymorphism. These results demonstrate that the (TTTTA)(n) polymorphism affects the Lp(a) expression independently of apo(a) size polymorphism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525120     DOI: 10.1016/s0021-9150(99)00137-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Repeat polymorphisms within gene regions: phenotypic and evolutionary implications.

Authors:  J D Wren; E Forgacs; J W Fondon; A Pertsemlidis; S Y Cheng; T Gallardo; R S Williams; R V Shohet; J D Minna; H R Garner
Journal:  Am J Hum Genet       Date:  2000-07-07       Impact factor: 11.025

Review 2.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

3.  The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians.

Authors:  Jill Rubin; Han Jo Kim; Thomas A Pearson; Steve Holleran; Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Atherosclerosis       Date:  2008-03-04       Impact factor: 5.162

4.  Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease.

Authors:  Raoudha Bahri; Esther Esteban; Pedro Moral; Mohsen Hassine; Khaldoun Ben Hamda; Hassen Chaabani
Journal:  Lipids Health Dis       Date:  2008-11-17       Impact factor: 3.876

5.  Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects.

Authors:  Enzo Emanuele; Emmanouil Peros; Piercarlo Minoretti; Colomba Falcone; Angela D'Angelo; Lorenza Montagna; Diego Geroldi
Journal:  BMC Cardiovasc Disord       Date:  2003-12-12       Impact factor: 2.298

6.  Marked variation in predicted and observed variability of tandem repeat loci across the human genome.

Authors:  Colm T O'Dushlaine; Denis C Shields
Journal:  BMC Genomics       Date:  2008-04-16       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.